M.D. Ph.D. David D. Chang - 16 May 2024 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
President and CEO, Director
Signature
/s/Earl Douglas, Attorney-in-Fact
Issuer symbol
ALLO
Transactions as of
16 May 2024
Net transactions value
+$1,000,001
Form type
4
Filing time
20 May 2024, 18:01:27 UTC
Previous filing
18 Mar 2024
Next filing
28 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Award $1,000,001 +344,828 +7.7% $2.90 4,810,106 16 May 2024 Direct F1
holding ALLO Common Stock 1,201,108 16 May 2024 See footnote F2
holding ALLO Common Stock 856,044 16 May 2024 See footnote F3
holding ALLO Common Stock 856,044 16 May 2024 See footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares of common stock were acquired directly from Allogene Therapeutics, Inc (the "Issuer") in a registered direct offering.
F2 Securities held in the name of the Chang 2006 Family Trust
F3 Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
F4 Securities held in the name of the RTC 2019 Trust dated October 1, 2019.